2026-07-16T11:24:30Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/271282026-01-11T01:18:07Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Velasco-de Andrés, María author Català, Cristina author Casadó-Llombart, Sergi author Martínez-Florensa, Mario author Simões, Inês author García-Luna, Joaquín author Mourglia-Ettlin, Gustavo author Zaragoza, Oscar author Carreras, Esther author Lozano, Francisco author 2020-12-16 Invasive fungal diseases represent an unmet clinical need that could benefit from novel immunotherapeutic approaches. Host pattern recognition receptors (e.g., Toll-like receptors, C-type lectins, or scavenger receptors) that sense conserved fungal cell wall constituents may provide suitable immunotherapeutic antifungal agents. Thus, we explored the therapeutic potential of the lymphocyte class I scavenger receptor CD5, a nonredundant component of the antifungal host immune response that binds to fungal β-glucans. Antifungal properties of the soluble ectodomain of human CD5 (shCD5) were assessed in experimental models of systemic fungal infection induced by pathogenic species ( and ). mechanistic studies were performed by means of fungus-spleen cell cocultures. shCD5-induced survival of lethally infected mice was dose and time dependent and concomitant with reduced fungal load and increased leukocyte infiltration in the primary target organ. Additive effects were observed after shCD5 was combined with suboptimal doses of fluconazole. addition of shCD5 to fungus-spleen cell cocultures increased the release of proinflammatory cytokines involved in antifungal defense (tumor necrosis factor alpha and gamma interferon) and reduced the number of viable organisms. The results prompt further exploration of the adjunctive therapeutic potential of shCD5 in severe invasive fungal diseases. Velasco-de Andrés M, Català C, Casadó-Llombart S, Martínez-Florensa M, Simões I, García-Luna J, Mourglia-Ettlin G, Zaragoza Ó, Carreras E, Lozano F 2020. The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection. Antimicrob Agents Chemother 65:10.1128/aac.01103-20. https://doi.org/10.1128/aac.01103-20 10.1128/AAC.01103-20 Antimicrobial Agents and Chemotherapy 33046489 https://hdl.handle.net/20.500.12105/27128 CD5 Candida albicans Cryptococcus neoformans Antifungal therapy Fluconazole Fungal infection Immunotherapy Scavenger receptors β-glucan The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection.